卡替洛尔 | 51781-06-7

• 物质功能分类: 原料药 - 循环系统用药 - 抗心律失常药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 卡替洛尔
• 中文别名: 喹诺酮心安；5-[3-(叔丁基氨基)-2-羟基丙氧基]-3,4-二氢-1H-喹啉-2-酮
• 英文名称: carteolol
• 英文别名: carteolol hydrochloride；Cartrol；5-(3-tert-butylamino-2-hydroxy-propoxy)-3,4-dihydro-1H-quinolin-2-one；5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-2(1H)-quinolinone；5-[3-(1,1-dimethylethyl)amino-2-hydroxypropoxy]-3,4-dihydro-2(1H)-quinolinone；5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one
• CAS: 51781-06-7
• 化学式: C₁₆H₂₄N₂O₃
• mdl: MFCD00864571
• 分子量: 292.378
• InChiKey: LWAFSWPYPHEXKX-UHFFFAOYSA-N

物化性质

• 沸点：
  434.3°C (rough estimate)
• 密度：
  1.0574 (rough estimate)
• 物理描述：
  Solid
• 溶解度：
  4.21e-01 g/L

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.562
• 拓扑面积：
  70.6
• 氢给体数：
  3
• 氢受体数：
  4

ADMET

代谢

肝脏的。

Hepatic.

来源:DrugBank

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用概要：目前没有关于母乳喂养期间使用卡替洛尔的数据。由于卡替洛尔可能广泛排入母乳中，因此在喂养新生儿时，优先选择其他β-肾上腺素能阻滞剂而不是口服卡替洛尔。两个月以上的婴儿肾功能更成熟，不太可能受到影响。 母亲使用卡替洛尔眼药对哺乳婴儿的风险应该很小，尽管一些指南指出，凝胶制剂比溶液更受推荐。在使用眼药水后，通过按压眼角处的泪管1分钟或更长时间，然后使用吸收性纸巾去除多余的溶液，可以显著减少到达母乳中的药物量。 ◉ 对哺乳婴儿的影响：一项研究调查了哺乳期间服用β-阻滞剂的母亲，发现服用任何β-阻滞剂的母亲其不良反应数量在数字上有所增加，但无统计学意义。尽管对照组的婴儿年龄与受影响的婴儿年龄相匹配，但受影响的婴儿的具体年龄并未说明。没有母亲服用卡替洛尔。具有类似母乳排泄特性的β-肾上腺素能阻滞剂在哺乳新生儿中引起了不良反应。 ◉ 对泌乳和母乳的影响：一项针对6名高催乳素血症和乳汁过多患者的研究发现，在使用普萘洛尔进行β-肾上腺素能阻断后，血清催乳素水平没有变化。目前没有关于正常哺乳期间β-阻断或卡替洛尔使用效果的报告。

◉ Summary of Use during Lactation:No data are available for the use of carteolol during breastfeeding. Because its excretion into breastmilk is probably extensive, other beta-adrenergic blocking drugs are preferred to oral carteolol while breastfeeding a neonate. Infants over 2 months of age have more mature kidney function and are less likely to be affected. Ophthalmic use of carteolol by the mother should pose little risk to the breastfed infant, although some guidelines state that gel formulations are preferred over solutions. substantially diminish the amount of drug that reaches the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue. ◉ Effects in Breastfed Infants:A study of mothers taking beta-blockers during nursing found a numerically, but not statistically significant increased number of adverse reactions in those taking any beta-blocker. Although the ages of infants were matched to control infants, the ages of the affected infants were not stated. None of the mothers were taking carteolol. Beta-adrenergic blocking drugs with similar breastmilk excretion characteristics have caused adverse effects in breastfed newborns. ◉ Effects on Lactation and Breastmilk:A study in 6 patients with hyperprolactinemia and galactorrhea found no changes in serum prolactin levels following beta-adrenergic blockade with propranolol. There are no reports on the effects of beta-blockade or carteolol use during normal lactation.

来源:Drugs and Lactation Database (LactMed)

安全信息

• 海关编码：
  2933790090
• 储存条件：
  库房应保持低温、通风和干燥。

制备方法与用途

类别：有毒物质
毒性分级：中毒
急性毒性：口服-小鼠 LD50: 810 毫克/公斤
可燃性危险特性：热分解排出有毒氮氧化物烟雾
储运特性：库房低温通风干燥
灭火剂：水、二氧化碳、泡沫、干粉

反应信息

• 作为反应物：
  描述：

  卡替洛尔 在 三乙胺 作用下， 以 吡啶 为溶剂， 反应 5.5h， 生成 4-[2-(4-Hydroxy-phenyl)-1-methoxycarbonyl-ethylcarbamoyl]-butyric acid 1-(tert-butylamino-methyl)-2-(2-oxo-1,2,3,4-tetrahydro-quinolin-5-yloxy)-ethyl ester
  参考文献：
  名称：

  人血浆中卡特洛尔的放射免疫分析

  摘要：

  开发了一种放射免疫测定法，用于直接测定人血浆中的一种新的β-肾上腺素受体阻滞剂卡替洛尔。将卡特洛尔酰化以形成O-戊二酰戊基醇，将其与牛血清白蛋白缀合以提供免疫原。卡特洛尔的抗体在新西兰白化病兔中产生。示踪剂是O-戊二烯基甲醇-酪氨酸甲酯共轭物的放射性碘标记的衍生物。该方法具有很高的灵敏度，使用0.1 ml血浆的定量浓度较低，约为0.4 ng卡替洛尔/ ml，并且具有良好的特异性，主要代谢物（8-羟基胆固醇）仅显示0.2％的交叉反应性。它是可重现的，与三次重复标准曲线的相对标准偏差大部分在+/- 8％之内。该方法目前用于监测临床样品中的卡替洛尔水平。

  DOI：

  10.1002/jps.2600700905
• 作为产物：
  描述：

  盐酸卡替洛尔 在 potassium carbonate 作用下， 以 水 为溶剂， 以95%的产率得到卡替洛尔
  参考文献：
  名称：

  Designing dendrimers for ocular drug delivery

  摘要：

  New series of phosphorus-containing dendrimers, having one quaternary ammonium salt as core and carboxylic acid terminal groups have been synthesized from generation 0 (3 carboxylic acid terminal groups) to generation 2 (12 carboxylic acid terminal groups). These dendrimers react with the neutral form of carteolol (an ocular anti-hypertensive drug used to treat glaucoma) to afford ion pair (saline) species. The solubility in water of these charged dendrimers depends on the generation considered: generation 0 (3 carteolol) is well soluble, whereas generation 1 (6 carteolol) and generation 2 (12 carteolol) are poorly soluble. These dendrimers have been tested in vivo, as vehicle for ocular drug delivery of carteolol to rabbits. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.10.017

文献信息

• DISUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160221965A1

  公开（公告）日：2016-08-04

  The present application relates to novel 2,5-disubstituted 6-(trifluoromethyl)pyrimidin-4(3H)-one derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular, renal, inflammatory and fibrotic diseases.

  本申请涉及新颖的2,5-二取代6-(三氟甲基)嘧啶-4(3H)-酮衍生物，其制备方法，其单独或与其他药物联合用于治疗和/或预防疾病，以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管、肾脏、炎症和纤维化疾病。
• [EN] QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS<br/>[FR] COMPOSÉS DONNEURS D'OXYDE NITRIQUE À BASE DE QUINONE
  申请人：NICOX SA

  公开号：WO2013060673A1

  公开（公告）日：2013-05-02

  The present invention relates to nitric oxide donor compounds having a quinone based structure, to processes for their preparation and to their use in the treatment of pathological conditions where a deficit of NO plays an important role in their pathogenesis.

  本发明涉及具有喹诚基结构的一氧化氮供体化合物，涉及其制备方法以及它们在治疗病理状况中的应用，其中一氧化氮缺乏在它们的发病机制中起重要作用。
• Dibenzyl Amine Compounds and Derivatives
  申请人：Chang George

  公开号：US20070213371A1

  公开（公告）日：2007-09-13

  Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

  二苯基胺化合物及其衍生物，含有这种化合物的药物组合物以及使用这种化合物提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他一些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，并据此治疗由高密度脂蛋白胆固醇水平低和/或低密度脂蛋白胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病在某些哺乳动物，包括人类。
• METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOXAMIDE AND THE PURIFICATION THEREOF FOR USE AS AN ACTIVE PHARMACEUTICAL INGREDIENT
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20180244670A1

  公开（公告）日：2018-08-30

  The present invention relates to a novel and improved process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I)

  本发明涉及一种用于制备式(I)的(4S)-4-(4-氰基-2-甲氧基苯基)-5-乙氧基-2,8-二甲基-1,4-二氢-1,6-萘啉-3-羧酰胺的新型改进工艺。
• RENIN INHIBITORS
  申请人：Jones Benjamin

  公开号：US20100210635A1

  公开（公告）日：2010-08-19

  Compounds, pharmaceutical compositions, kits and methods are provided for use with Renin that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.

  提供了用于与Renin一起使用的化合物、药物组合物、试剂盒和方法，其中包括从以下组中选择的化合物：其中变量如本文所定义。